Barclays PLC Cuts Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Barclays PLC decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 373,876 shares of the company's stock after selling 98,028 shares during the period. Barclays PLC owned 0.08% of Elanco Animal Health worth $4,528,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ELAN. Steward Partners Investment Advisory LLC boosted its position in shares of Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after purchasing an additional 2,264 shares in the last quarter. DDD Partners LLC acquired a new stake in Elanco Animal Health in the fourth quarter worth about $5,974,000. Harbor Capital Advisors Inc. increased its holdings in shares of Elanco Animal Health by 24.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after acquiring an additional 209,734 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Elanco Animal Health by 14.0% in the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company's stock valued at $5,349,000 after purchasing an additional 45,795 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN opened at $9.45 on Monday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company's fifty day moving average price is $10.03 and its 200 day moving average price is $11.62. The company has a market capitalization of $4.69 billion, a PE ratio of 23.63, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.08 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Stifel Nicolaus dropped their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, April 14th. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Elanco Animal Health has an average rating of "Hold" and an average price target of $14.67.

Insider Buying and Selling

In other news, Director Lawrence Erik Kurzius acquired 10,000 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the purchase, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by insiders.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.